Lornoxicam-d₄is intended for use as an internal standard for the quantification of lornoxicam by GC- or LC-MS. Lornoxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties.¹It inhibits production of thromboxane B₂from arachidonic acid in HEL human erythroleukemic cells (IC₅₀= 3 nM), which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F_1αfrom arachidonic acid in Mono-Mac-6 cells (IC₅₀= 8 nM), which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC₅₀values of 65 and 54 µM, respectively. It reduces carrageenan-induced paw edema in rats when administered intravenously at doses ranging from 0.1 to 9 mg/kg.²Formulations containing lornoxicam have been used in the management of postoperative pain.

1.Berg, J., Fellier, H., Christoph, T., et al.The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitroInflamm. Res.48(7)369-379(1999) 2.Buritova, J., and Besson, J.M.Potent anti-inflammatory/analgesic effects of lornoxicam in comparison to other nsaids: A c-Fos study in the ratInflammopharmacology5(4)331-341(1997)